Biopharmaceutical company developing ziltivekimab, an antibody intended to reduce major adverse cardiovascular events in patients with chronic kidney disease and atherosclerotic cardiovascular disease
Biopharmaceutical company developing ziltivekimab, an antibody intended to reduce major adverse cardiovascular events in patients with chronic kidney disease and atherosclerotic cardiovascular disease. Its research focused on inflammation in cardio-renal diseases. Novo Nordisk agreed to acquire the company in 2020.